Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

BACKGROUND: Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socializ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Frenck, Robert W., Klein, Nicola P., Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L., Walter, Emmanuel B., Senders, Shelly, Bailey, Ruth, Swanson, Kena A., Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V., Cooper, David, Jennings, Timothy, Brandon, Donald M., Thomas, Stephen J., Türeci, Özlem, Tresnan, Dina B., Mather, Susan, Dormitzer, Philip R., Şahin, Uğur, Jansen, Kathrin U., Gruber, William C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Massachusetts Medical Society 2021
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8174030/
https://ncbi.nlm.nih.gov/pubmed/34043894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2107456
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares